According to the Zhitong Finance App, Maipu Medical (301033.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 190 million yuan, an increase of 20.30% over the previous year. Net profit attributable to shareholders of listed companies was 56.5805 million yuan, an increase of 19.62% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 53.9375 million yuan, an increase of 17.26% over the previous year. Basic earnings per share were $0.85.
During the reporting period, the company achieved a total sales revenue of 96.0759 million yuan for closed and leak-proof products, an increase of 11.13% over the previous year. Among them, in March 2026, the Tianjin Pharmaceutical Procurement Center issued the “Notice Concerning the Announcement of the Results of the Beijing-Tianjin-Hebei “3+N” Alliance Hard Brain (Spine) Membrane Patch Volume Linkage Procurement Project (Project Number: LH-HD2025-5)”, and the company's two meningeal products were successfully selected. By the end of the reporting period, implementation had been carried out one after another in Tianjin, Henan, Fujian and other places. In the future, the company will continue to monitor the collection progress to ensure the smooth execution of the procurement results. In addition, dural medical adhesive products are used for auxiliary sealing of the dura mater suture to prevent cerebrospinal fluid from leaking. Together with two dural repair products, Radial Membrane® Absorbable Hard (Spine) Membrane Patches and Ruikang® Hard (Spine) Membrane Patches, they have formed a comprehensive sealing and leak-proof solution. At the same time, this product can also be used in conjunction with currently common dural repair materials.